Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes
Ioanna Papakitsou,1 George Vougiouklakis,1 Moses S Elisaf,2 Theodosios D Filippatos1 1Department of Internal Medicine, School of Medicine, University of Crete, University Hospital of Heraklion, Heraklion, Crete, Greece; 2Department of Internal Medicine, School of Medicine, University of Ioannina, Io...
Guardado en:
Autores principales: | Papakitsou I, Vougiouklakis G, Elisaf MS, Filippatos TD |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/81d3e66b11ba4b9092eaf7a119d98752 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice
por: Nguyen T, et al.
Publicado: (2020) -
Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
por: Avgerinos I, et al.
Publicado: (2019) -
The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence
por: Gupta M, et al.
Publicado: (2021) -
Effect of Dapagliflozin and Magnesium Supplementation on Renal Magnesium Handling and Magnesium Homeostasis in Metabolic Syndrome
por: Hwee-Yeong Ng, et al.
Publicado: (2021) -
Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China
por: Yaohui Jiang, et al.
Publicado: (2021)